

Cyclacel Pharmaceuticals develops oral therapies to treat cancers and other critical diseases. Among its major competitors, Cyclacel Pharmaceuticals is ranked in 5th place for NPS while GlaxoSmithKline is 1st, and Bristol Myers Squibb is 2nd.Their current market cap is $8.28M